Compare Davita Inc (DVA) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Entegris Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Entegris Inc trades at $164.6 (market cap $24.78B). The key difference: Entegris Inc is far larger — about 2.2× Davita Inc's market cap, and Entegris Inc pays a 0.25% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Entegris Inc for 41 Days on average.
| DVA | ENTG | |
|---|---|---|
Market Cap | $11.29B | $24.78B |
Volume | 582,204 | 2,648,320 |
Sector | Health | Technology |
52-Week High | $240.96 | $184.00 |
52-Week Low | $103.87 | $68.80 |
Typical Hold Time | 113 Days | 41 Days |
Enterprise Value | $24.01B | $27.99B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
ENTG trades at $166.32, down 0.34% on the day, with strong technical momentum showing bullish moving averages and key resistance at $168. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected October 29. Revenue remains stable at $3.2B (2025) with improving net margins from 5.12% (2023) to 7.37% (2025), though valuation ratios appear elevated with P/E at 83.16.
Wall Street maintains strong bullish sentiment with 70% buy ratings and $182.43 consensus price target, representing 9.7% upside. Key risks include high debt levels ($3.98B) and semiconductor industry cyclicality. The upcoming Q3 earnings and November Investor Day will be critical catalysts for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
